Tagged with M

Europe The general manager for Sandoz Iberia, Joaquin Rodrigo, comments on the intricacies of the Spanish healthcare system, the main trends driving generics and biosimilars in the country and shares his perspective on recent policy changes at a national and continental level. With over ten years of experience with the company,…

EUCOPE EUCOPE’s Secretary-General Dr. Alexander Natz sees both opportunities and pitfalls with the EU HTA procedure, saying that the next three years will decide the crucial steps and whether the new procedure leads to reduced burdens for developers and faster patient access to innovative therapies.   With the entry into force…

Global With the rise of more transmissible variants and the reduced efficacy of outpatient monoclonal antibody therapies, the market for oral antivirals is expected to climb to new heights this year. Pfizer to take the lead, followed by Merck, and possibly, Shionogi. According to Airfinity’s recent COVID-19 treatment revenue forecast, the…

MEA The Middle East and Africa, combined, represent the world’s fifth largest regional pharma market. According to IQVIA’s recent figures, most of the largest markets grew, although slowly due to COVID lockdowns, with Saudi Arabia in the top position. Multinational companies continue to “dominate” the region with Gilead Sciences experiencing huge…

USA Stephen J. Ubl, President & CEO of Pharmaceutical Research and Manufacturers of America (PhRMA) discusses the organisation’s initiatives to address health inequity in the US along with its opposition to the provisions in the Biden administration’s Build Back Better Act to lower costs and improve access. He also comments on…

Spain Weeks after a mosquito forced the recall of 765,000 doses of Moderna’s vaccine manufactured in Spain, the country’s top medicines regulator called for new inspection procedures, praised the loyalty of the Spanish pharma industry and asked if the industry is going “too lean?” Speaking at a conference in Madrid on…

Global While the pharma industry provides the vital medicines needed to treat diseases and keep populations healthy, it is also responsible for carbon emissions of an intensity almost 55 percent higher than those of the automotive industry.* Lesser known than the link between the production of Active Pharmaceutical Ingredients (APIs) and…

Italy Medac Pharma Italy’s Giovanni Sala describes the Italian affiliate’s unique portfolio of haematology, onco-urology, and neurosurgery products, as well as generics, and outlines the challenges of the Italian market.   … in Italy we have developed a dual strategy: on one side in-licence local generic products; while on the other…

Italy SIFI’s Fabrizio Chines outlines how the company is progressing in European ophthalmic markets, explains the added value it is bringing to the glaucoma field, and tells us about its orphan drug for acanthamoeba keratitisis.    … Germany and the UK are the next strategic targets, but in those markets we will…

USA When the FDA gave Novartis the historic green light for Kymriah – the first gene therapy approved in the United States – in 2017, the agency declared that it was “ushering in a new approach” to the treatment of cancer and other serious and life-threatening diseases. Today, more than 20…

Global At the recent Global Biopharma press briefing on COVID-19, held by the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), industry leaders took on the issue of vaccine inequity, challenging the view that intellectual property waivers could be the answer. 13.7 billion doses of vaccines have been delivered and 11…

Italy Massimo Scaccabarozzi, President of Farmindustria, discusses Italy’s response to the pandemic and the association’s key priorities, which include maintaining Italy’s position as a European leader in terms of production. Italy has a key role to play in the EU objective of guaranteeing continuity of supply during emergencies.   Italy became…